Advertisements


Nektar reports 48% overall response rate in urothelial cancer for NKTR-214 combo

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 12th, 2019

Nektar bladder cancer response rate exceeded expectation, says Mizuho

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 12th, 2019

Iovance reports 27% objective response rate in study of cervical carcinoma

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

Iovance reports objective response rate of 37% in Cohort 2 of C-144-01 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

Nektar Plummets Amid Concern Over Cancer-Drug Trial Results

Nektar Therapeutics lost a third of its value in Monday trading after response rates in melanoma and kidney cancer patients decreased in a mid-stage trial of the company’s cancer drug in combination with Bristol-Myers Squibb Co.’s Opdivo......»»

Category: topSource: moneycentralJun 4th, 2018

We just got a lot of updates on the state of cancer treatments — here are the winners and losers (BLUE, NKTR, LOXO, MRK, BMY)

Over the weekend at the American Society of Clinical Oncologists meeting, a lot of updates and new data were presented.  It sent stocks all over the place Monday with the biggest movers being Bristol-Myers Squibb, Nektar, Loxo and Bluebird bi.....»»

Category: topSource: businessinsiderJun 4th, 2018

Why Nektar Therapeutics Shares Are Tumbling

Nektar Therapeutics (NASDAQ: NKTR) saw its shares get nearly halved in Monday’s session after the company released preliminary data from its early stage cancer study. The preliminary results........»»

Category: blogSource: 247wallstJun 4th, 2018

Dynavax abstract shows 40% response rate in head and neck cancer

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Nektar Starts Phase I/II Combo for Advanced Solid Tumors

Nektar (NKTR) initiates dosing in a phase I/II study, evaluating the combination of its two novel immuno-oncology agent.....»»

Category: worldSource: nytApr 12th, 2018

Cancer Genetics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Strategic Business Updates

RUTHERFORD, N.J., April 16, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (NASDAQ:CGIX), a leader in enabling precision medicine for immuno-oncology and genomic .....»»

Category: earningsSource: benzingaApr 16th, 2019

American Express reports March net write-off rate 2.5% vs. 2.4% prior month

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2019

Bank of America reports March default rate 2.78% vs. 2.62% last month

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2019

Synchrony reports March net charge off rate 5.24% vs. 4.98% last month

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2019

These 3 Falling Knives Are Expected to Outperform

Nektar Therapeutics tops the listRelated Stocks: NKTR, STMP, ADAP,.....»»

Category: worldSource: nytApr 12th, 2019

Tikcro Technologies Reports Fourth Quarter and Full Year 2018 Results

NESS-ZIONA, Israel, April 12, 2019 /PRNewswire/ -- High Level Pre-Clinical Results Showed in AACR 2019 Annual Conference Tikcro Technologies Ltd. (OTCQB:TIKRF), a pre-clinical stage developer of antibodies for cancer immune-t.....»»

Category: earningsSource: benzingaApr 12th, 2019

Sub-Saharan Africa"s growth rate slashed

The World Bank has cut the economic growth rate of Sub-Saharan Africa to 2.8 percent this year, as the region again fails to meet expected targets. Sam Holder reports......»»

Category: videoSource: reutersApr 10th, 2019

Experimental cancer "vaccine" shows promising early results, CNBC reports

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 8th, 2019

Johnson & Johnson wins trial over man"s talc-cancer claim, Bloomberg reports

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 7th, 2019

Moleculin Biotech reports precilinical data in pancreatic cancer candidates

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 3rd, 2019

Nektar (NKTR) Down 17.1% Since Last Earnings Report: Can It Rebound?

Zacks.....»»

Category: topSource: redinewsApr 1st, 2019

TCR2 Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., April 1, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today reported financial re.....»»

Category: earningsSource: benzingaApr 1st, 2019